ArticleThe journal of obstetrics and gynaecology research2026
Aggressive Clinical Course of Uterine Tumor Resembling Ovarian Sex Cord Tumor (UTROSCT) Harboring GREB1::SS18 Fusion Gene: A Case Report.
Article in The journal of obstetrics and gynaecology research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We report a fatal case of malignant uterine tumor resembling ovarian sex cord tumor (UTROSCT) harboring the GREB1::SS18 fusion gene. A 64-year-old woman presented with a uterine tumor extending into the inferior vena cava, along with multiple hepatic and bone metastases. Although imaging suggested low-grade endometrial stromal sarcoma, histopathology revealed sex cord-like structures. GREB1::SS18 fusion was identified by RNA sequencing and independently confirmed by RT-PCR and Sanger sequencing. Despite multimodal therapy, the patient died 26 months postoperatively. While most UTROSCTs follow a benign course, rare malignant cases exist. Literature review suggests GREB1-rearranged UTROSCTs are more aggressive, occurring in older patients with larger tumors compared to ESR1-rearranged tumors. This is the first report of a fatal outcome associated with the GREB1::SS18 fusion. This case underscores the importance of molecular diagnosis for predicting malignant potential in UTROSCT, especially when atypical aggressive features are present.
Indexed as
Identifiers
42850055What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.